TY - JOUR
T1 - New-onset heart failure in association with severe hypertension during trastuzumab therapy
AU - Herrmann, Joerg
AU - Herrmann, Sandra M.
AU - Haddad, Tufia C.
N1 - Publisher Copyright:
© 2014 Mayo Foundation for Medical Education and Research.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Heart failure is a dreaded complication of trastuzumab therapy in women with breast cancer overexpressing the human epidermal growth factor receptor (HER)-2. Experimental studies have pointed out that the HER-2 signaling pathway is important in the adaptation to high afterload conditions and its inactivation leads to cardiac decompensation. Herein, we report on 2 patients with breast cancer who were receiving trastuzumab monotherapy and required hospital admission for new-onset heart failure. This occurred at a time of unprecedented blood pressure elevations, in one case due to cessation of antihypertensive medications and in the other case due to a scleroderma crisis. Although trastuzumab may not have been the precipitating factor for blood pressure dyscontrol in these patients, severe, uncontrolled hypertension may have been the precipitating factor for trastuzumab-related acute heart failure. These 2 cases add to previous reports recognizing systemic hypertension as a risk factor for the development of trastuzumab cardiotoxicity and translate experimental observations of the significance of the HER-2 signaling pathway to the bedside. Pending further confirmation, the present observations may raise awareness of the need for appropriate monitoring and control of systemic hypertension in patients receiving trastuzumab, or potentially any other HER-2-targeted therapy.
AB - Heart failure is a dreaded complication of trastuzumab therapy in women with breast cancer overexpressing the human epidermal growth factor receptor (HER)-2. Experimental studies have pointed out that the HER-2 signaling pathway is important in the adaptation to high afterload conditions and its inactivation leads to cardiac decompensation. Herein, we report on 2 patients with breast cancer who were receiving trastuzumab monotherapy and required hospital admission for new-onset heart failure. This occurred at a time of unprecedented blood pressure elevations, in one case due to cessation of antihypertensive medications and in the other case due to a scleroderma crisis. Although trastuzumab may not have been the precipitating factor for blood pressure dyscontrol in these patients, severe, uncontrolled hypertension may have been the precipitating factor for trastuzumab-related acute heart failure. These 2 cases add to previous reports recognizing systemic hypertension as a risk factor for the development of trastuzumab cardiotoxicity and translate experimental observations of the significance of the HER-2 signaling pathway to the bedside. Pending further confirmation, the present observations may raise awareness of the need for appropriate monitoring and control of systemic hypertension in patients receiving trastuzumab, or potentially any other HER-2-targeted therapy.
KW - Abbreviations and Acronyms
KW - ECG electrocardiogram
KW - ED emergency department
KW - EF ejection faction
KW - ER estrogen receptor
KW - ErbB gene symbol for the epidermal growth factor receptor
KW - HER human epidermal growth factor receptor
KW - PR progesterone receptor
UR - http://www.scopus.com/inward/record.url?scp=84919675764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919675764&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2014.08.011
DO - 10.1016/j.mayocp.2014.08.011
M3 - Article
C2 - 25441402
AN - SCOPUS:84919675764
VL - 89
SP - 1734
EP - 1739
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 12
ER -